Improved Survival Regardless of Age
Treatment of older patients with VIDAZA®
The median age of diagnosis of myelodysplastic syndromes (MDS) is 70+.1 Survival without active treatment is short in higher-risk MDS; age makes no substantial difference.2,3
Older patients with a good performance status can benefit from active treatment.4
Treatment approach should take into account the patient and the disease: IPSS prognosis, marrow blast counts, cytogenetics, cytopenias, transfusional history. The decision to treat should be based on functional rather than chronological age.5
“Advanced age should not exclude a patient with MDS from appropriate treatment…. Age alone should not be considered a surrogate marker for functional decline or comorbidities.”1
– Stauder et al.
VIDAZA® is the first and only agent proven to improve overall survival vs. CCR in patients ≥75 years old4
In patients ≥75 years of age, OS rates at 2 years were significantly higher with VIDAZA® vs. CCR; 55% vs. 15%, respectively (p=0.001). After two years:4
VIDAZA® is generally well tolerated in this elderly population, with discontinuations due to an adverse event occurring in 13% of VIDAZA® patients vs. 8% of CCR patients.4 For more on Adverse Events, visit Adverse Events Management and Monitoring.
Find out more about clinical trial results.
- Stauder R et al. J Natl Compr Canc Netw 2008. 6: 927-934.
- Greenberg P et al. Blood 1997. 89: 2079-88.
- Nosslinger T et al. Ann Oncol.2010. 21: 120-5.
- Seymour JF et al. Crit Rev Oncol Hematol 2010. 76: 218-227.
- Pallis AG et al. Eur J Cancer 2010. 46: 1502-1513.
a. MDS-specific Indication
VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:
- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:
Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ≥20% to <30% as AML patients.
This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.